243 related articles for article (PubMed ID: 26709918)
21. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Wang LH; Chan JL; Li W
Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506
[TBL] [Abstract][Full Text] [Related]
22. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells.
Chang CJ; Chiu JH; Tseng LM; Chang CH; Chien TM; Wu CW; Lui WY
Eur J Clin Invest; 2006 Aug; 36(8):588-96. PubMed ID: 16893382
[TBL] [Abstract][Full Text] [Related]
23. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
24. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
[TBL] [Abstract][Full Text] [Related]
25. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
27. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
Pérez-Gómez E; Andradas C; Blasco-Benito S; Caffarel MM; García-Taboada E; Villa-Morales M; Moreno E; Hamann S; Martín-Villar E; Flores JM; Wenners A; Alkatout I; Klapper W; Röcken C; Bronsert P; Stickeler E; Staebler A; Bauer M; Arnold N; Soriano J; Pérez-Martínez M; Megías D; Moreno-Bueno G; Ortega-Gutiérrez S; Artola M; Vázquez-Villa H; Quintanilla M; Fernández-Piqueras J; Canela EI; McCormick PJ; Guzmán M; Sánchez C
J Natl Cancer Inst; 2015 Jun; 107(6):djv077. PubMed ID: 25855725
[TBL] [Abstract][Full Text] [Related]
28. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
29. BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.
Hao L; ElShamy WM
Int J Cancer; 2007 Jul; 121(1):39-46. PubMed ID: 17278098
[TBL] [Abstract][Full Text] [Related]
30. Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.
Caiazza F; Harvey BJ; Thomas W
Mol Endocrinol; 2010 May; 24(5):953-68. PubMed ID: 20211985
[TBL] [Abstract][Full Text] [Related]
31. Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancer.
Nakamura Y; Felizola SJ; Kurotaki Y; Fujishima F; McNamara KM; Suzuki T; Arai Y; Sasano H
Prostate; 2013 May; 73(6):590-5. PubMed ID: 23060014
[TBL] [Abstract][Full Text] [Related]
32. Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells.
Schmucker H; Blanding WM; Mook JM; Wade JF; Park JP; Kwist K; Shah H; Booth BW
Cell Oncol (Dordr); 2018 Apr; 41(2):159-168. PubMed ID: 29181633
[TBL] [Abstract][Full Text] [Related]
33. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
[TBL] [Abstract][Full Text] [Related]
34. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
[TBL] [Abstract][Full Text] [Related]
35. Preferential estrogen receptor β ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy.
Ruddy SC; Lau R; Cabrita MA; McGregor C; McKay BC; Murphy LC; Wright JS; Durst T; Pratt MA
Mol Cancer Ther; 2014 Jul; 13(7):1882-93. PubMed ID: 24785256
[TBL] [Abstract][Full Text] [Related]
36. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
38. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
Parris AB; Zhao Q; Howard EW; Zhao M; Ma Z; Yang X
J Exp Clin Cancer Res; 2017 Feb; 36(1):28. PubMed ID: 28193239
[TBL] [Abstract][Full Text] [Related]
39. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.
Gougelet A; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):110-22. PubMed ID: 17478088
[TBL] [Abstract][Full Text] [Related]
40. Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.
Jandial DD; Krill LS; Chen L; Wu C; Ke Y; Xie J; Hoang BH; Zi X
Molecules; 2017 Mar; 22(3):. PubMed ID: 28335434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
